# Revamp Medical

> Revamp Medical is an Israeli medical device company building the Doraya catheter, a temporary, adjustable flow-reducing catheter for patients hospitalized with acute heart failure. Deployed in the infrarenal inferior vena cava for up to 12 hours, Doraya is designed to relieve venous congestion and improve response to diuretic therapy in patients who respond poorly to standard drugs - addressing the local mechanism of diuretic resistance rather than relying on systemic drugs or dialysis. Founded in 2016 and based in Netanya, the company won FDA Breakthrough Device designation in 2020 and closed a KCK Medtech-led Series A in 2023 to fund U.S. clinical trials.

- **Founded:** 2016
- **Headquarters:** Netanya, Israel
- **Founders:** Rafi Benary (Co-founder & CTO), Lihu Avitov (Co-founder & Board Member)
- **Team size:** ~15 employees
- **Products:** Doraya Catheter
- **Notable:** FDA Breakthrough Device designation granted for the Doraya catheter in July 2020, Completed first-in-human feasibility study; data presented at THT 2022, First-in-human results published in JACC: Basic to Translational Science (March 2022)

## Products & services

- **Doraya Catheter** — A temporary, manageable flow-reducing central venous catheter deployed in the infrarenal inferior vena cava (IVC) for up to 12 hours. It lets clinicians temporarily control central venous pressure, renal afterload, and venous return to reduce congestion and improve diuretic efficacy in acute heart failure patients with poor or delayed response to diuretics.

## Achievements

- FDA Breakthrough Device designation granted for the Doraya catheter in July 2020
- Completed first-in-human feasibility study; data presented at THT 2022
- First-in-human results published in JACC: Basic to Translational Science (March 2022)
- First patient enrolled in the U.S. DORAYA-HF Early Feasibility Study (2022)
- Closed Series A financing led by KCK Medtech (2023)
- Recruited former NeuroPace CEO Mike Favet as CEO (2024)

## Latest updates

- **2024-03** — Revamp Medical appointed Mike Favet, former CEO of NeuroPace, as Chief Executive Officer and board member.
- **2023-05** — Closed a Series A preferred stock financing led by KCK Medtech, with Arkin, Accelmed and Michael Berman participating, to fund U.S. clinical trials.
- **2022-10** — First patient enrolled in the U.S. DORAYA-HF Early Feasibility Study evaluating the Doraya catheter in acute heart failure.
- **2022-03** — First-in-human feasibility data published in JACC: Basic to Translational Science and presented at THT 2022.

## Links

- Website: https://revampmedical.com
- LinkedIn: https://www.linkedin.com/company/revamp-medical

---

Profile page: https://yespress.io/revamp-medical-ltd
Published by YesPress — https://yespress.io
Last updated: 2026-07-10